LoL, PNV are merely providing the substrate material for the implantation, BTM doesn't need any trials to be used in this way. Sure there will need to be trials and approvals for the implantation of Islet Cells but that is no burden for Polynovo. Its merely demonstrating it's potential usefulness in another application.
That being said while interesting and another potential addressable market and perhaps opens up other possibilities, it also isn't going to impact revenues in the near future either since AFAIK it has no stake in that company. Which might be the reason for the shorts hammering away today.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)